Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Respiratory Restriction Leaded by Conventional or Minimally Invasive Sugical Repair of Oesophageal Atresia in Children (RestriMIS2)

12 de noviembre de 2026 actualizado por: University Hospital, Angers

Assessment of Respiratory Restriction Caused by Chest Wall Abnormalities Following Conventional or Minimal Invasive Surgical Repair of Type III Esophageal Atresia in School Age Children

Children born with esophageal atresia need surgery shortly after birth. For many years, the standard operation was a thoracotomy, an opening in the chest that can sometimes lead to changes in the shape of the chest wall. Although these changes are visible on X rays, doctors still do not fully understand how much they affect breathing later in childhood. A newer, less invasive technique called thoracoscopy uses small incisions and appears to cause fewer chest deformities, but its impact on lung function has not yet been clearly established.

This study aims to compare the breathing capacity of children aged 6 to 9 who were operated on using either thoracotomy or thoracoscopy. The main question is whether one group is more likely to develop restrictive lung syndrome, a condition in which the lungs cannot expand normally. To answer this, the study relies on lung function tests and chest X rays performed during routine follow up visits.

Beyond this primary goal, the study also examines other possible breathing problems, the presence of chest wall abnormalities, and factors that might influence lung health, such as nutrition, physical activity, associated malformations, and overall quality of life.

A total of at least 360 children across France will participate. They are identified through national registries and invited during scheduled follow up consultations.

Descripción general del estudio

Tipo de estudio

De observación

Inscripción (Estimado)

360

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Francoise SCHMITT, MD
  • Número de teléfono: +33 2 41 35 42 90
  • Correo electrónico: FrSchmitt@chu-angers.fr

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Amiens, Francia, 80054
        • CHU Amiens, Département de Pédiatrie, centre d'activité "chirurgie pédiatrique viscérale"
        • Contacto:
        • Investigador principal:
          • Philippe BUISSON, MD
      • Angers, Francia, 49933
        • CHU Angers, Service Urgences, Médecine, Psychiatrie et Chirurgie Pédiatriques
        • Contacto:
        • Contacto:
        • Investigador principal:
          • francoise SCHMITT, MD
      • Clermont-Ferrand, Francia, 63003
        • CHU Clermont-Ferrand, Service de pédiatrie générale et multidisciplinaire
        • Contacto:
        • Investigador principal:
          • Carole EGRON, MD
      • Dijon, Francia, 21000
        • CHU Dijon, Service de chirurgie pédiatrique
        • Contacto:
        • Investigador principal:
          • Michel FRANCOIS, MD
      • Grenoble, Francia, 38700
        • CHU Grenoble, Service de chirurgie pédiatrique
        • Contacto:
        • Investigador principal:
          • Pierre-Yves RABATTU, MD
      • Le Kremlin-Bicêtre, Francia, 94275
        • Hôpital Bicêtre, AP-HP, Chirurgie Viscérale Pédiatrique
        • Contacto:
        • Investigador principal:
          • Khadidja KHADIR, MD
      • Lyon, Francia, 69677
        • Hospices Civils de Lyon, Service d'Hepato-Gastroentérologie et Nutrition Pédiatrique
        • Contacto:
        • Investigador principal:
          • Nicolas CARON, MD
      • Nantes, Francia, 44093
        • CHU Nantes, Hôpital Mère-Enfant, Service de Chirurgie Infantile
        • Contacto:
        • Investigador principal:
          • Audrey GUINOT, MD
      • Paris, Francia, 75015
        • Hôpital Necker Enfants Malades, AP-HP, Service de Pneumologie et Allergologie Pédiatriques
        • Contacto:
        • Investigador principal:
          • Rola ABOU TAAM, MD
      • Strasbourg, Francia, 67098
        • CHU Strasbourg, Service de chirurgie pédiatrique
        • Contacto:
      • Toulouse, Francia, 31059
        • CHU Toulouse, Service de Chirurgie Viscérale Pédiatrique
        • Contacto:
        • Investigador principal:
          • Aurelie LE MANDAT, MD

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

6 años a 10 años (Niño)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra de probabilidad

Población de estudio

Eligible patients in both groups are mainly identified through the national esophageal atresia registry (RENATO, CRACMO, CHU Lille).

Descripción

For thoracoscopy group:

Inclusion Criteria:

  • Child operated on by thoracoscopy for type 3 AO (excluding long gap) according to Ladd's classification
  • Child aged 6 to 10 years old
  • Consent from parents (or legal guardians) and the child's agreement to participate in the study

Exclusion Criteria:

  • Heart or lung malformation diagnosed at birth and requiring surgery
  • Conversion from thoracoscopy to thoracotomy during the procedure
  • Child who has had more than one thoracic surgery (reoperation for AO, other reasons for thoracic surgery including heart surgery)
  • For Thoracotomy group*:

Inclusion Criteria :

--Child operated on by thoracotomy for type 3 AO (excluding long gap) according to the Ladd classification

  • Child aged 6 to 10 years old
  • Consent from parents (or legal guardians) and the child's agreement to participate in the study

Exclusion Criteria:

  • Heart or lung malformation diagnosed at birth and requiring surgery
  • Child who has had more than one thoracic surgery (reoperation for AO, other reason for thoracic surgery including heart surgery)
  • Child operated on for type 3 AO via thoracotomy (excluding long gap) according to Ladd's classification

For each patient who underwent thoracoscopic surgery included in the study, two patients who had thoracotomy, matched according to known or suspected confounding factors for restrictive syndromes from the RestriMIS1 (NCT04136795) study**, will be included.

*It's possible that some children had multiple consecutive surgeries. In those cases, if one of the procedures was a thoracotomy, the children will be classified in the thoracotomy group (the more major surgery).

**Prematurity, birth weight, presence of tracheomalacia, and GERD during the neonatal period (clinically and/or on additional tests)

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: COHORT
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
thoracoscopy group

minimally invasive surgical approach

thoracotomy arm

conventionnal surgical approach

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
to assess the presence of a restrictive lung syndrome in patients with type 3 esophageal atresia (EA) depending on the type of surgical approach used (conventional or minimally invasive).
Periodo de tiempo: Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)

Rate of restrictive syndrome according to the type of surgical approach (conventional or minimally invasive), defined by spirometry data: FEV1/FVC > -1.64 Z-score and FVC < -1.64 Z-score, according to the ATS/ERS-GLI (American Thoracic Society & European Respiratory Society - Global Lung Initiative) recommendations published in 2012 (Quanjer) and reviewed en 2022.

Lung function tests can be done up to 2 years after the multidisciplinary consultation (Visit 0)

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
to evaluate the importance of restrictive syndrome
Periodo de tiempo: importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)

The importance of restrictive syndrome is classified into 3 levels: mild restrictive syndrome [-1.64 > z-score ≥ -2.5], moderate [-2.5 > z-score ≥ -4.0], or severe [-4.0 > z-score]).

importance of restrictive syndrome can be evaluated up to 2 years after the multidisciplinary consultation (visit 0)
Looking for other respiratory parameters
Periodo de tiempo: the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation

Other respiratory changes are examined by measuring other respiratory parameters (forced vital capacity, FEF 25-75, Tiffeneau ratio, reversibility), which help highlight obstructive or mixed syndromes (FEV1/FVC < -1.64 and FVC < -1.64 z-score) when present

the link between chest skeletal abnormalities found on chest X-rays and lung impact can be evaluated up to 2 years after the multidisciplinary consultation
to assess the link between chest skeletal abnormalities found on chest X-rays and lung impact
Periodo de tiempo: until spirometry is completed, within a maximum period of 2 years

The following factors are considered when estimating the risk of association with or without a restrictive syndrome (history data like prematurity or types of malformations associated with AO III, surgical and medical care data in the neonatal period and childhood, growth data at one year and at 6-10 years), lung care, physical activity, the PedsQL score (for children aged 6 to 10), and responses to the EA-QoL questionnaire (for children aged 8 to 10).

until spirometry is completed, within a maximum period of 2 years
rate of postoperative complications and any necessary reoperations
Periodo de tiempo: up to 2 years after the multidisciplinary consultation

The rate of postoperative complications is assessed by type of surgery as well as any necessary follow-up surgeries.

up to 2 years after the multidisciplinary consultation
Respiratory-related quality of life during childhood
Periodo de tiempo: up to 2 years after the multidisciplinary consultation

It will be estimated through both need for lung care, physical activity, PedsQL score (for children aged 6 to 10), and EA-QoL questionnaire (for children aged 8 to 10).

up to 2 years after the multidisciplinary consultation
to assess the existence of a cause-and-effect link between the restrictive syndrome and the surgical technique used
Periodo de tiempo: through study completion, within a maximum of 24 months

The acceptability of the existence of a causal link is assessed using sensitivity analysis, which estimates how robust the results are while taking into account missing data and different clinical scenarios (including a per-protocol analysis in addition to the intention-to-treat analysis).

through study completion, within a maximum of 24 months
to assess the mortality rate
Periodo de tiempo: through study completion, an average 7 years

The death rate for each surgery group will be described based on the follow-up in the study, that is, the date of the surgery (combined data for all patients in the registry).

through study completion, an average 7 years
Looking for lung volumes variations
Periodo de tiempo: the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation

Lung volume variations will be measured by dynamic respiratory MRI data

the link between chest skeletal abnormalities found on chest X-rays and MRI lung volumes can be evaluated up to 2 years after the multidisciplinary consultation

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

2 de diciembre de 2026

Finalización primaria (Estimado)

2 de diciembre de 2032

Finalización del estudio (Estimado)

2 de diciembre de 2032

Fechas de registro del estudio

Enviado por primera vez

22 de septiembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Publicado por primera vez (Actual)

17 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

17 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

INDECISO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir